HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

BMC Gastroenterology

Research Article

Massimo Marignani¹  Cristina Mastropietro²  Caterina Furlan³  Tommaso Stroffolini³  Olga Mitidieri⁴  Claudio Puoti⁴  Giuseppe Barbaro⁵  Maria Elena Bonaventura⁶  Roberto Monarca⁷  Giorgio Barbarini⁸  Angelo Barlattani⁹  Cecilia D’Ambrosio^1,10  Arnaldo Andreoli^1,10  Adriano M Pellicelli^1,10  Lucia Miglioresi^1,10  Antonio Picardi^1,11  Umberto Vespasiani Gentilucci^1,11  Mario Romano^1,12  Fabrizio Mecenate^1,13  Ettore Mazzoni^1,14  Lorenzo Nosotti^1,15  Pascal Vignally^1,16 

[1] Department of Digestive and Liver Disease, Azienda Ospedaliera Sant'Andrea, Via Grottarossa, 1035/1039, Rome, Italy;Department of Infectious Disease Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy;Department of Infectious and Tropical Disease Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy;Department of Internal Medicine and liver unit Ospedale Generale di Marino, Viale XXIV Maggio, 00047, Marino Rome, Italy;Department of Medical Pathophysiology, University of Rome La Sapienza, Viale del Policlinico 155, 00161, Rome, Italy;Infectious Disease Ospedale San Camillo de Lellis, Via John Fitzgerald Kennedy, 02100, Rieti, Italy;Infectious Disease Ospedale di Belcolle strada Sammartinese, 01100, Viterbo, Italy;Infectious and Parasitic Diseases, Policlinico San Matteo P.zzale Golgi,2, 27100, Pavia, Italy;Liver Unit ASL RM/A, Rome, Italy;Liver Unit Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense, 87 00149, Rome, Italy;Liver Unit Campus Biomedico University, Via Álvaro del Portillo, 21 00128, Rome, Italy;Liver Unit Ospedale Sandro Pertini, Via dei Monti Tiburtini 385, 00157, Rome, Italy;Liver Unit Ospedale Villa Betania, Via Niccolò Piccolomini 27, 00165, Rome, Italy;Liver Unit Policlinico Casilino, Via Casilina, 1049-00169, Rome, Italy;Medicine of Migration National Institute for Migrant Health and Poverty, Via di S. Gallicano 25/a, 00153, Rome, Italy;National Institute of Health, Viale Regina Elena 299, 00161, Rome, Italy;

关键词: Genotype 1a;    HCV genotype 1 subtypes;    Sustained virological response;    Antiviral therapy;    Pegylated interferon;   

DOI  :  10.1186/1471-230X-12-162

 received in 2012-06-18, accepted in 2012-11-13,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundThe impact of viral subtype on the rate of sustained virological response (SVR) to antiviral therapy in patients chronically infected with hepatitis C genotype 1 subtype 1a and 1b has not been extensively investigated. The aim of this study is to determine whether the HCV genotype 1 subtypes 1a and 1b respond differently to treatment with PEGylated interferon (PEG-IFN) plus ribavirin.MethodsFor 48 weeks, 388 “naïve”genotype 1 patients were treated weekly with PEG-IFN α-2a or PEG-INF α-2b combined with daily ribavirin (1000–1200 mg/day). The numbers of patients in whom HCV-RNA was undetectable were compared after 4 (rapid virological response, RVR), 12 (early virological response, EVR), and 48 (end treatment virological response, ETR) weeks of treatment as well as 24 weeks after the last treatment (sustained virological response, SVR).ResultsThe rate of SVR was higher in subtype 1a patients than subtype 1b patients (55% vs. 43%; p < 0.02). Multiple logistic regression analysis showed that infection with genotype 1a (odds ratio(OR) : 1.8; 95% confidence interval (CI): 1.4 to 4.1), age < 50 years (OR:7.0; 95% CI 1.1 to 21.2), alanine aminotransferase level (ALT)<100 IU/ml (OR:2.1; 95% CI: 1.3 to3.5), HCV-RNA < 5.6 log10 IU/ml (OR: 3.2; 95% CI: 2.7 to 6.9) and fibrosis score < S3 (OR: 3.8; 95% CI:3.2 to 7.4), were all independent predictors of SVR.ConclusionDual antiviral therapy is more effective against HCV subtype 1a than against subtype 1b and this difference is independent of other factors that may favour viral clearance.Trial registrationClinicalTrials.gov Identifier: NCT01342003

【 授权许可】

CC BY   
© Pellicelli et al.; licensee BioMed Central Ltd. 2012